Correction: Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting

Ji-Young Kim; Ji-Hae Han; Geon Park; Young-Woo Seo; Cheol-Won Yun; Byung-Chul Lee; Jeehyeon Bae; Ae Ran Moon; Tae-Hyoung Kim

doi:10.18632/oncotarget.25604

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting

PDF | How to cite

Oncotarget. 2018; 9:26977-26977. https://doi.org/10.18632/oncotarget.25604

Metrics: PDF 1346 views | ?

Ji-Young Kim^1,*, Ji-Hae Han^1,*, Geon Park², Young-Woo Seo³, Cheol-Won Yun⁴, Byung-Chul Lee⁵, Jeehyeon Bae⁶, Ae Ran Moon^1,* and Tae-Hyoung Kim^1,*

¹Department of Biochemistry, Chosun University School of Medicine, Dong-Gu, Gwang-Ju, Korea
²Department of Laboratory Medicine, Chosun University School of Medicine, Dong-Gu, Gwang-Ju, Korea
³Korea Basic Science Institute Gwang-Ju Center, Chonnam National University, Buk-Gu, Gwang-Ju, Korea
⁴School of Life Science and Biotechnology, Korea University, Seoul, Korea
⁵Geno ux. Co., Ltd., Sejong City, Korea
⁶School of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul, Korea
^*These authors equally contributed to this work

Published: June 01, 2018

This article has been corrected: The correct Grant Support information is given below:

GRANT SUPPORT

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (Grant no. 2010-0009201 and NRF-2013R1A1A2058254 to TH Kim), by the Ministry of Science, ICT, and Future Planning (NRF-2014R1A2A1A11050442 to TH Kim), and by the National R&D Program for Cancer Control funded by the Ministry of Health and Welfare of the Korean government (Grant no. HI14C2025 to TH Kim).

Original article: Oncotarget. 2016; 7:32449-32461. DOI: https://doi.org/10.18632/oncotarget.8719.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25604

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting